Nota clínica
Uso del 177Lu-DOTATATE como terapia en carcinomas de tiroides yodorrefractarios
Use of 177Lu-dotatate in the treatment of iodine refractory thyroid carcinomas
Leído
687
Vecesse ha leído el artículo
218
Total PDF
469
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 8 | 4 | 4 | 8 |
| 2025 7 | 1 | 1 | 2 |
| 2025 4 | 1 | 0 | 1 |
| 2025 2 | 3 | 2 | 5 |
| 2024 11 | 7 | 3 | 10 |
| 2024 10 | 2 | 2 | 4 |
| 2024 9 | 1 | 2 | 3 |
| 2024 4 | 7 | 0 | 7 |
| 2023 11 | 9 | 2 | 11 |
| 2023 10 | 2 | 4 | 6 |
| 2023 6 | 1 | 3 | 4 |
| 2023 3 | 7 | 5 | 12 |
| 2023 2 | 1 | 2 | 3 |
| 2022 11 | 1 | 2 | 3 |
| 2022 8 | 1 | 2 | 3 |
| 2022 4 | 3 | 4 | 7 |
| 2022 3 | 16 | 2 | 18 |
| 2022 2 | 1 | 2 | 3 |
| 2021 11 | 3 | 0 | 3 |
| 2021 10 | 1 | 0 | 1 |
| 2021 9 | 2 | 4 | 6 |
| 2021 8 | 1 | 0 | 1 |
| 2021 7 | 5 | 2 | 7 |
| 2021 4 | 2 | 0 | 2 |
| 2021 3 | 30 | 6 | 36 |
| 2020 1 | 1 | 0 | 1 |
| 2020 12 | 2 | 2 | 4 |
| 2020 11 | 1 | 0 | 1 |
| 2020 10 | 1 | 2 | 3 |
| 2020 9 | 0 | 1 | 1 |
| 2020 8 | 3 | 4 | 7 |
| 2020 5 | 1 | 2 | 3 |
| 2020 3 | 1 | 0 | 1 |
| 2020 2 | 1 | 0 | 1 |
| 2020 1 | 1 | 0 | 1 |
| 2019 10 | 1 | 0 | 1 |
| 2019 7 | 1 | 0 | 1 |
| 2019 5 | 1 | 4 | 5 |
| 2019 4 | 2 | 4 | 6 |
| 2019 2 | 22 | 2 | 24 |
| 2019 1 | 139 | 72 | 211 |
| 2018 12 | 27 | 19 | 46 |
| 2018 11 | 19 | 18 | 37 |
| 2018 10 | 16 | 14 | 30 |
| 2018 9 | 27 | 6 | 33 |
| 2018 8 | 11 | 0 | 11 |
| 2018 7 | 20 | 1 | 21 |
| 2018 6 | 11 | 0 | 11 |
| 2018 5 | 10 | 0 | 10 |
| 2018 4 | 2 | 0 | 2 |
| 2018 2 | 3 | 0 | 3 |
| 2018 1 | 4 | 1 | 5 |
| 2017 12 | 1 | 0 | 1 |
| 2017 11 | 2 | 0 | 2 |
| 2017 10 | 0 | 1 | 1 |
| 2017 9 | 2 | 2 | 4 |
| 2017 7 | 3 | 0 | 3 |
| 2017 5 | 1 | 1 | 2 |
| 2017 4 | 3 | 1 | 4 |
| 2017 3 | 17 | 1 | 18 |
| 2016 1 | 0 | 1 | 1 |
| 2016 12 | 0 | 1 | 1 |
| 2016 11 | 0 | 3 | 3 |
| 2016 10 | 0 | 1 | 1 |
Mostrar todo
